Mepolizumab is a humanized monoclonal antibody that targets interleukin-5, a cytokine that plays a central role in eosinophilic inflammation, which is present in 20 to 40% of patients with chronic ...

We studied the prednisone-sparing effect of mepolizumab, a monoclonal antibody against interleukin-5, in a rare subgroup of patients who have sputum eosinophilia and airway symptoms despite ...

Among those diagnosed with COPD for at least 9 years, mepolizumab reduced the annualized rate of moderate or severe exacerbations by 24% compared with placebo (95% CI, 0.60-0.97).

If you continue to have this issue please contact [email protected]. Patients receiving mepolizumab vs. placebo had a smaller number of moderate/severe exacerbations at weeks 52 and 104.

If you continue to have this issue please contact [email protected]. Mepolizumab reduced the risk for a first severe exacerbation and a first exacerbation requiring ED visit and/or ...

Adding mepolizumab to inhaled triple therapy significantly improved exacerbation outcomes compared with placebo in adults with chronic obstructive pulmonary disease (COPD), based on data from the ...

Compared with placebo, the time to first moderate or severe exacerbation was longer with mepolizumab. HealthDay News — For patients with chronic obstructive pulmonary disease (COPD) with a ...

Mepolizumab targets IL-5, addressing eosinophilic inflammation in 20%-40% of COPD patients, marking its fifth US indication. The phase 3 MATINEE trial showed a 21% reduction in annualized moderate ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab)as an add-on maintenance treatment for adult patients with inadequately ...

LONDON--(BUSINESS WIRE)--GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an ...

GlaxoSmithKline announced positive results from the pivotal phase 3 study of mepolizumab in the treatment of patients with hypereosinophilic syndrome (HES). HES is a rare group of inflammatory ...

WASHINGTON, May 2 (UPI) --The agency responsible for drug safety in Germany has questioned the efficacy of mepolizumab, a drug for severe asthma, after finding what it called inadequate clinical ...